Vireo Growth (VREOF) Return on Capital Employed (2021 - 2026)
Vireo Growth's (VREOF) quarterly Return on Capital Employed came in at 0.91% in Q1 2026, down 679.0% year-on-year from 0.16% in Q1 2025, and up 593.95% quarter-over-quarter from 0.18% in Q4 2025.
Vireo Growth (VREOF) Return on Capital Employed (2021 - 2026) Analysis & Trends
Vireo Growth has disclosed Return on Capital Employed across 6 years of filings, most recently posting 0.91% for Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 0.91%, down 679.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.91% (down 679.0% YoY), and the FY2025 annual result was 0.29%, down 1448.0% from the prior year.
- Return on Capital Employed came in at 0.91% for Q1 2026 at Vireo Growth, up from 0.18% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 527.87% in Q1 2024 to a low of 528.74% in Q4 2023.
- The 5-year median for Return on Capital Employed is 0.91% (2026), against an average of 31.89%.
- Across the five-year window, Return on Capital Employed tumbled 52365 bps in 2023 and soared 54218 bps in 2024, its largest moves.
- Vireo Growth's Return on Capital Employed stood at 5.08% in 2022, then slumped by 10303 bps to 528.74% in 2023, then jumped by 103 bps to 13.44% in 2024, then sank by 101 bps to 0.18% in 2025, then jumped by 594 bps to 0.91% in 2026.
- The last three Return on Capital Employed figures came in at 0.91% (Q1 2026), 0.18% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 8.52% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 27.58% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 21.43% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 20.04% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 7.34% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 6.92% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -1.92% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 14.85% |
| 10 | Vireo Growth | - | - | 59.30 Mn | 0.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.91% |
| Dec 31, 2025 | -0.18% |
| Sep 30, 2025 | -0.01% |
| Jun 30, 2025 | 1.33% |
| Mar 31, 2025 | 7.70% |
| Dec 31, 2024 | 13.44% |
| Sep 30, 2024 | 30.21% |
| Jun 30, 2024 | 362.84% |
| Mar 31, 2024 | 527.87% |
| Dec 31, 2023 | -528.74% |
| Sep 30, 2023 | 173.96% |
| Jun 30, 2023 | -3.04% |
| Mar 31, 2023 | 1.87% |
| Dec 31, 2022 | -5.08% |
| Sep 30, 2022 | -10.99% |
| Jun 30, 2022 | -13.57% |
| Mar 31, 2022 | -16.32% |
| Dec 31, 2021 | -13.73% |
| Sep 30, 2021 | -11.73% |
| Jun 30, 2021 | -12.35% |